Canopy Biosciences™ LLC, a leading provider of gene editing and gene expression products and services, announced today the launch of RareSeq, a new error corrected sequencing service that vastly increases the sensitivity of genetic testing over traditional methods. This technology, exclusively licensed from Washington University and developed by Todd Druley, MD, PhD and Andrew Young, MD, PhD, removes the errors generated in traditional next generation sequencing (NGS) to unveil rare mutations previously indistinguishable from background noise. Canopy will launch RareSeq at the American Association for Cancer Research (AACR) conference beginning on March 29 and will showcase the technology to conference attendees in their booth #2650. The service will be available for sale immediately.
With the RareSeq service, researchers send samples to Canopy who then prepare them using a proprietary protocol that includes unique molecule indices/identifiers (UMIs). Canopy then sequences the samples and uses a novel bioinformatics tool to computationally identify ...
